Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Immunology | Infections and Infectious Diseases | Family Medicine
Clinical Trials: HIV Infections
A listing of clinical trials currently looking for volunteers to enroll in HIV Infections studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : The University of Alabama at Birmingham Alabama Vaccine Research Clinic
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART
Birmingham : University of Alabama Birmingham NICHD CRS (5096)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Birmingham : University of Alabama at Birmingham
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Birmingham : University Of Alabama At Birmingham
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Birmingham : University of Alabama at Birmingham (UAB)
Strategic Timing of Antiretroviral Treatment
View More »
Hobson City : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Arizona
Phoenix : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Phoenix : Phoenix Children's Hospital
Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens
Phoenix : Spectrum Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Phoenix : Pueblo Family Physicians
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Phoenix : Spectrum Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
View More »
Phoenix : Spectrum Medical Group
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
California
Bakersfield : Franco Felizarta, MD
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
Bakersfield : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Bakersfield : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Beverly Hills : AHF Research Center
A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System
Beverly Hills : AHF Research Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
View More »
Beverly Hills : Pacific Oak Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Beverly Hills : AIDS Healthcare Foundation
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Beverly Hills : Pacific Oaks Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Beverly Hills : AHF Research Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Coronado :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
Garden Grove : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Hayward : Kaiser Permanente
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Hayward : Kaiser Permanente
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Irvine : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
La Jolla : Scripps Clinic
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Long Beach : Miller Children's Hospital Long Beach NICHD CRS (5093)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Long Beach : Living Hope Clinical Foundation
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Long Beach : VA Long Beach Healthcare System
Pilot Study of Raltegravir Lipodystrophy IISP
Long Beach : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Los Angeles : AIDS Research Alliance
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART
Los Angeles : UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CR (3601)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Los Angeles : Childrens Hospital Los Angeles NICHD CRS (5090)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Los Angeles : USC/Los Angeles County Medical Center NICHD CRS (5048)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Los Angeles : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Los Angeles : UCLA CARE Center CRS (601)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Los Angeles : UCLA Center for AIDS Research and Education
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Los Angeles : OASIS Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : Peter J. Ruane, MD, Inc.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : Anthony Mills MD Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : Anthony Mills MD Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : OASIS Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : Peter J. Ruane, M.D., Inc.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : Kaiser Permanente
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : Anthony Mills MD Inc
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Los Angeles : Peter J Ruane MD Inc.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Los Angeles : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Los Angeles : Peter J. Ruane, MD, Inc.
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Los Angeles : Anthony Mills MD, Inc
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Los Angeles : Southern California Permanente Medical Group
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Los Angeles : Anthony Mills, MD Internal Medicine
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
Los Angeles : UCLA CARE-4-Families (LABAC CRS)
Strategic Timing of Antiretroviral Treatment
Los Angeles : University of Southern California
Strategic Timing of Antiretroviral Treatment
Los Angeles : VA Greater Los Angeles Healthcare System
Strategic Timing of Antiretroviral Treatment
Los Angeles :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
Los Angelos : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Newport Beach : Orange Coast Medical Group
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Newport Beach : Orange Coast Medical Group
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Oakland : East Bay AIDS Center Medical Group
Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Oakland : Alameda County Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Oakland : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Oakland : Alta Bates Summit Medical Center, East Bay AIDS Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Orange : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Orange : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Palm Desert : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Palm Springs : Desert Medical Group Inc.
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Palo Alto : Stanford University
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Palo Alto : Stanford University
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Sacramento : Kaiser Permanente Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Sacramento : Kaiser Permanente
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Sacramento : University of California, Davis
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Sacramento : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Sacramento : Kaiser Permanente Medical Group
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Sacramento : UCDavis Research Office at CARES
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
San Diego : Univ of California, San Diego (4601)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
San Diego : Ucsd, Avrc Crs (701)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
San Diego : La Playa Medical Group and Clinical Research
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Diego : La Playa Medical Group and Clinical Research
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Diego : La Playa Medical Group and Clinical Research
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
San Diego : La Playa Medical Group and Clinical Research
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
San Diego : Ucsd Antiviral Research Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Diego : UCSD Mother-Child-Adolescent Program
Strategic Timing of Antiretroviral Treatment
San Diego : Naval Medical Center San Diego NMCSD
Strategic Timing of Antiretroviral Treatment
San Francisco : Quest Clinical Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
San Francisco : Benchmark Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
San Francisco : University of California San Francisco - San Francisco General Hospital
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
San Francisco : Quest Clinical Research
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
San Francisco : Kaiser Permanente
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Francisco : Metropolis Medical
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Francisco : Kaiser Permanente San Francisco
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Francisco : Metropolis Medical
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Francisco : Metropolis Medical
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
San Francisco : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
San Francisco : TPMG--Clinical Trials Unit
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
San Francisco : Kaiser Permanente Medical Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Francisco : San Francisco General Hospital
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Francisco :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
San Francisco : University of California, San Francisco
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
San Francisco, : Univiversity of California San Francisco NICHD CRS (5091)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Stanford : Stanford University
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Stanford : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Torrance : Harbor (UCLA) Medical Center NICHD CRS (5045)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Torrance : Harbor-UCLA Med. Ctr. CRS (603)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Colorado
Aurora : University of Colorado, Denver NICHD CRS (5052)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Aurora : University of Colorado Hospital CRS (6101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Denver : University of Colorado Health Sciences Center
A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication
Denver : Denver Public Health CRS
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Denver : Denver Infectious Disease Consultants, PLLC
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
View More »
Denver : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Denver : Denver Infectious Disease Consultants, PLLC
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Lafayette : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Connecticut
New Haven : Yale University School of Medicine
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
New Haven : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
New Haven : Yale University School of Medicine
Strategic Timing of Antiretroviral Treatment
Norwalk : Circle CARE Center, LLC
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Norwalk : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
View More »
West Haven : Va Connecticut Healthcare System
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Delaware
Wilmington : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
District of Columbia
Washington : Howard University Washington, DC NICHD CRS (5044)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Washington : Washington Hospital Center NICHD CRS (5023)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Washington : Children's National Med. Ctr. Washington DC NICHD CRS (5015)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Washington : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Washington : Georgetown University CRS (GU CRS) (1008)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
View More »
Washington : Whitman Walker Health
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Washington : Georgetown University
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
Washington : Capital Medical Associates, P.C.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Washington : Dupont Circle Physicians Group, P.C.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Washington : Capital Medical Associates, PC
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Washington : Dupont Circle Physicians Group, P.C
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Washington : Dupont Circle Physician's Group
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Washington : Children'S National Medical Center
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Washington : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Washington : Dupont Circle Physician's Group
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Washington : Whitman-Walker Health
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Washington : Capital Medical Associates, PC
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Washington : Whitman-Walker Clinic
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
Washington : Georgetown University
Strategic Timing of Antiretroviral Treatment
Washington : George Washington University Medical Center
Strategic Timing of Antiretroviral Treatment
Washington : Washington DC VA Medical Center
Strategic Timing of Antiretroviral Treatment
Florida
Coral Gables : Sanitas Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Daytona Beach :
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Daytona Beach : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Fort Lauderdale : Therafirst Medical Centers
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Fort Lauderdale : Gary Richmond MD, PA, Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
View More »
Fort Lauderdale : Gary Richmond, MD
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Fort Lauderdale : Gary J. Richmond,M.D., P.A.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Fort Lauderdale : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Fort Lauderdale : Gary J. Richmond,M.D.,P.A.
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Fort Lauderdale : Children's Diagnostic and Treatment Center, Inc.
Strategic Timing of Antiretroviral Treatment
Fort Myers : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Fort Pierce : Midway Immunology and Research
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Fort Pierce : Midway Immunology & Research Center, LLC
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Fort Pierce : Midway Immunology and Research Center
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Fort Pierce : Midway Immunology and Research Center
Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
Fort Pierce : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Ft. Lauderdale : South Florida CDC Ft. Lauderdale NICHD CRS (5055)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Jacksonville : Univ. of Florida Jacksonville NICHD CRS (5051)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Jacksonville : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Jacksonville : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Jacksonville : University of Florida Health Services Center
Strategic Timing of Antiretroviral Treatment
Jacksonville : UF CARES/Rainbow Center
Strategic Timing of Antiretroviral Treatment
Jacksonville : University of Florida, Jacksonville
Strategic Timing of Antiretroviral Treatment
Miami :
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Miami : University of Miami Pediatric Perinatal HIV/AIDS CRS (4201)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Miami : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Miami : The Kinder Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Miami : The Kinder Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Miami : The Kinder Medical Group
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Miami : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Miami : University Of Miami School Of Medicine
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Miami : University of Miami School of Medicine, AIDS Clinical Research unit
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Miami : University of Miami
Strategic Timing of Antiretroviral Treatment
Miami : University of Miami Pediatric Immunology
Strategic Timing of Antiretroviral Treatment
Miami Beach : Wohlfeiler, Piperato and Associates, LLC
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Miami Beach : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Miami Beach : Wohlfeiler, Piperato and Associates, LLC
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Orlando : Call for Information (Investigational Site 0022)
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)
Orlando : Orlando Immunology Center
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Orlando : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Orlando : Orlando Immunology Center
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Orlando : Orlando Immunology Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Orlando : ValuHealth MD, LLC
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Orlando : Orlando Immunology Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Orlando : Idocf/Valuhealthmd, Llc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Orlando : Idocf/Valuhealthmd, Llc
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Orlando : Orlando Immunology Center
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Orlando : IDOCF/ValuhealthMD, LLC
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Orlando : Orlando Immunology Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Orlando : Orlando Immunology Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Orlando : Orange County Health Department/Hug Me
Strategic Timing of Antiretroviral Treatment
Orlando : Orlando Immunology Center
Strategic Timing of Antiretroviral Treatment
Orlando :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
Pensacola : Infectious Diseases Associates of Northwest Florida
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Pensacola : Infectious Diseases Associates of NW FL, P.A.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Pensacola : Infectious Diseases Associates NW FL, PA
Strategic Timing of Antiretroviral Treatment
Port Saint Lucie :
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Safety Harbor : Health Positive
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Safety Harbor : AHF Health Positive Tampa Bay
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Safety Harbor : AHF Health Positive - Tampa Bay
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Safety Harbor : Barry M. Rodwick, M. D.
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
St Petersburg : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
St. Petersburg : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Tampa : Tampa General Hospital NICHD CRS (5111)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Tampa : USF - Tampa NICHD CRS (5018)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Tampa : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Tampa : St. Joseph's Comprehensive Research Institute
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Tampa : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Tampa : St. Joseph's Comprehensive Research Institute
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Tampa : USF Health - HIV Clinical Research Unit
Strategic Timing of Antiretroviral Treatment
Vero Beach : Treasure Coast Infectious Disease Consultants
Strategic Timing of Antiretroviral Treatment
West Palm Beach :
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
West Palm Beach : Triple O Medical Services, P.A.
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Georgia
Atlanta : AIDS Research Consortium of Atlanta
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART
Atlanta : Aids Research Consortium Of Atlanta
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Atlanta : Grady Infectious Diseases Program
Kaletra Sex/Gender Pharmacokinetics (PK) Study: A Switch From Twice Daily to Once Daily Lopinavir/Ritonavir
Atlanta : Atlanta ID Group, PC
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Atlanta : Atlanta ID Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
View More »
Atlanta : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Atlanta : Aids Research Consortium Of Atlanta
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Augusta : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Decatur : Infectious Disease Specialists of Atlanta
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Decatur : Infectious Disease Specialists of Atlanta
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Decatur : Infectious Disease Specialists of Atlanta
Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
Decatur : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Decatur : Infectious Disease Specialists of Atlanta
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Douglasville : American Red Cross
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Macon : Mercer University Mercer Medicine
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Macon :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
Marietta : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Riverdale : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Savannah : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Illinois
Birmingham : Cooper Green Mercy Hospital (CGMH)
Strategic Timing of Antiretroviral Treatment
Chicago : The Ruth M. Rothstein CORE Center
A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication
Chicago : Chicago Children's CRS (4001)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chicago : Rush University Cook County Hospital NICHD CRS (5083)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chicago : Northwestern University CRS (2701)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
View More »
Chicago : Howard Brown Health Center
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-Based HAART in Advanced HIV Disease
Chicago : University of Chicago Hospital
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-Based HAART in Advanced HIV Disease
Chicago : University of Illinois Medical Center
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-Based HAART in Advanced HIV Disease
Chicago : Rush University Medical Center
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-Based HAART in Advanced HIV Disease
Chicago : Rush University - Stroger Hospital of Cook County
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Chicago : John H. Stroger, Jr. Hospital of Cook County/Ruth M. Rothstein CORE Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Chicago : Northwestern University Division of Infectious Diseases
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Chicago : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Chicago : Howard Brown Health Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Chicago : Lurie Children's Hospital
Strategic Timing of Antiretroviral Treatment
Chicago : University of Illinois at Chicago
Strategic Timing of Antiretroviral Treatment
Chicago : Mt. Sinai Hospital
Strategic Timing of Antiretroviral Treatment
Peoria : Call for Information (Investigational Site 9001)
Isentress Re-examination Study (MK-0518-115 AM1)
Springfield : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Indiana
Indianapolis : Indiana University Infectious Diseases
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Iowa
Iowa City : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Kentucky
Lexington : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Louisiana
New Orleans : Tulane University NICHD CRS (5095)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
New Orleans : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
New Orleans : Tulane University Medical Center
Strategic Timing of Antiretroviral Treatment
Maryland
Baltimore : Johns Hopkins University NICHD CRS (5092)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Baltimore : University of Maryland NICHD CRS (5094)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Baltimore : University of Maryland, School of Medicine
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Baltimore : Evelyn Jordan Center
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Baltimore : University of Maryland, Institute of Human Virology
R5 Integrase Study in HIV-1 Naive Patients
View More »
Bethesda : National Institutes of Health Clinical Center
Strategic Timing of Antiretroviral Treatment
Bethesda : Walter Reed National Military Medical Center
Strategic Timing of Antiretroviral Treatment
Lutherville : Johns Hopkins University
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Silver Spring : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Massachusetts
Boston : Boston Medical Center Ped. HIV Program NICHD CRS (5011)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Boston : Brigham and Women's Hospital NICHD CRS (5110)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Boston : Children's Hospital of Boston NICHD CRS (5009)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Boston : Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Boston : Brigham and Women's Hosp. ACTG CRS (107)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
View More »
Boston : Massachusetts General Hospital ACTG CRS (101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Boston : Community Research Initiative of New England
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Boston : Community Research Initiative (CRI)
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Boston : Boston Medical Center
Strategic Timing of Antiretroviral Treatment
Boston : Boston Medical Center Section of Pediatric ID
Strategic Timing of Antiretroviral Treatment
Boston : Children's Hospital, Boston
Strategic Timing of Antiretroviral Treatment
Boston : Community Research Initiative of New England
Strategic Timing of Antiretroviral Treatment
Boston : Massachusetts General Hospital
Subclinical Atherosclerosis in HIV-infected Patients
Springfield : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Springfield : Baystate Infectious Diseases Clinical Research
Strategic Timing of Antiretroviral Treatment
Worcester : WNE Maternal Pediatric Adolescent AIDS CRS (7301)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Michigan
Ann Arbor : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Berkley : Be Well Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Berkley : Be Well Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Berkley : Be Well Medical Center
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Berkley : Be Well Medical Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
View More »
Detroit : Hutzel Hospital NICHD CRS (5089)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Detroit : Wayne State University/Children's Hospital of Michigan NICHD CRS (5041)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Detroit : Wayne State Univ. CRS
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Detroit : Henry Ford Hosp. CRS (31472)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Detroit : Henry Ford Hospital
Post-Exposure Prophylaxis in Health Care Workers
Detroit : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Detroit : Henry Ford Health System
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Detroit : Wayne State University CRS
Strategic Timing of Antiretroviral Treatment
Detroit : Henry Ford Health System
Strategic Timing of Antiretroviral Treatment
East Lansing : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Grosse Pointe Woods : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Lansing : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Southfield : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
St. Louis : Central West Clinical Research Inc
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Minnesota
Minneapolis : HIV Program Hennepin County Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Minneapolis : Hennepin County Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Minneapolis : Hennepin County Medical Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Minneapolis : Clinic 42 And International Travel Clinic
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Minneapolis : Minneapolis Medical Research Foundation, Hennepin County Medical Center
Strategic Timing of Antiretroviral Treatment
View More »
Rochester : Mayo Clinic
Strategic Timing of Antiretroviral Treatment
Missouri
Kansas City : The Kansas City Free Health Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Kansas City : The Kansas City Free Health Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Kansas City :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
Saint Louis : Call for Information (Investigational Site 0006)
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)
St Louis : Central West Clinical Research, Inc.
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
View More »
St. Louis : Washington U CRS (2101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
St. Louis : Washington University School of Medicine
Heart Function in HIV-Negative Children Exposed to HIV and HAART
St. Louis : Central West Clinical Research Inc
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
New Jersey
Camden : Cooper Univ. Hosp. CRS (31476)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Camden : Cooper University Hospital
Strategic Timing of Antiretroviral Treatment
Hillsborough : ID Care
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Hillsborough : I.D. Care Associates PA
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Hillsborough :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
View More »
Long Branch : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Morristown : Morristown Memorial Hospital
RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)
Neptune : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Newark : New Jersey Medical School CRS (2802)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Newark : New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Newark : Saint Michael's Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Newark : Saint Michael's Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Newark : New Jersey Medical School Adult Clinical Research Center
Strategic Timing of Antiretroviral Treatment
Somers Point : South Jersey Infectious Disease
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Somers Point : South Jersey Infectious Disease
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Somers Point : South Jersey Infectious Disease
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
New Mexico
Santa Fe : Southwest CARE Center
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Santa Fe :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
New York
Bronx :
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Bronx : Bronx-Lebanon Hospital IMPAACT CRS (6901)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Bronx : Jacobi Med. Ctr. Bronx NICHD CRS (5013)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Bronx : Jacobi & North Central Bronx Hospitals
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Bronx : James J Peters Vamc
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
View More »
Bronx : Jacobi Medical Center
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Bronx : Montefiore Medical Center
Strategic Timing of Antiretroviral Treatment
Bronx : Bronx-Lebanon Hospital Center
Strategic Timing of Antiretroviral Treatment
Buffalo : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Ithaca : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Manhasset : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Manhasset : North Shore University Hospital / Division of Infectious Diseases
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Manhasset : North Shore-Long Island Jewish Health System
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Monticello : Upper Delaware Valley Infectious Diseases, Pc
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Mt. Vernon : Greiger Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Mt. Vernon : Greiger Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Mt. Vernon : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
New York : Columbia IMPAACT CRS (4101)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
New York : Metropolitan Hospital NICHD CRS (5003)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
New York : New York University NY NICHD CRS (5012)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
New York : NY Univ. HIV/AIDS CRS (401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
New York : Cornell CRS (7804)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
New York : Bellevue Hospital
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
New York : Aids Com. Res. Init. Of Amer
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
New York : Ricky K Hsu, MD, PC
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
New York : Aaron Diamond AIDS Research Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
New York : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
New York : ACRIA
Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease
New York : Mount Sinai School Of Medicine
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
New York : Chelsea Village Medical
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
New York : Cornell CRS
Strategic Timing of Antiretroviral Treatment
Rochester : Strong Memorial Hospital, University of Rochester NICHD CRS (5057)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Rochester : Univ. of Rochester ACTG CRS (1101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Rochester : University of Rochester
Comparing Raltegravir Genital Tract Distribution in HIV-Infected Men and Women
Rochester : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Stony Brook : SUNY Stony Brook NICHD CRS (5040)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Stony Brook : SUNY Stony Brook
Strategic Timing of Antiretroviral Treatment
Syracuse : Suny Upstate Medical University
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Valhalla : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
North Carolina
Chapel Hill :
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Chapel Hill : University of North Carolina at Chapel Hill
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
Chapel Hill : Unc Aids Crs (3201)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Chapel Hill : The University of North Carolina - Chapel Hill
Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
Chapel Hill : AIDS Clinical Trials Unit
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
View More »
Chapel Hill : UNC AIDS Clinical Trials Unit
Strategic Timing of Antiretroviral Treatment
Chapel Hill : The University of North Carolina at Chapel Hill
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
Charlotte : ID Consultants, P.A.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Charlotte : ID Consultants, P.A.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Charlotte : ID Consultants, P.A.
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Charlotte : Carolinas Medical Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Charlotte : Id Consultants, Pa
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Durham : Duke University Medical Center (DUMC) Pediatric CRS (4701)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Durham : Duke Univ. Med. Ctr. Adult CRS (1601)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Durham : Duke University Medical Center
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Durham : Duke University
Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
Durham : Duke University Medical Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Durham : Duke University Medical Center
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Durham : Duke Pediatric
Strategic Timing of Antiretroviral Treatment
Durham : Duke University
Strategic Timing of Antiretroviral Treatment
Greensboro : Regional Center for Infectious Disease
Strategic Timing of Antiretroviral Treatment
Greenville : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Huntersville : Rosedale Infectious Diseases
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Raleigh : Wake County Human Services
Strategic Timing of Antiretroviral Treatment
Wilmington : Registry Coordinating Center
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.
Wilmington : GSK Investigational Site
Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
Winston-Salem : Wake Forest University Health Sciences
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Winston-Salem : Wake Forest University Health Sciences
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Winston-Salem : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Winston-Salem : Wake Forest University Health Sciences
Strategic Timing of Antiretroviral Treatment
Ohio
Cincinnati : Univ. of Cincinnati CRS (2401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Cincinnati : University Of Cincinnati College Of Medicine
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Cincinnati : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Cleveland : Case CRS (2501)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Cleveland : Metro Health CRS (2503)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
View More »
Cleveland : Case Western Reserve University
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Columbus : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Columbus : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Columbus : The Ohio State University Medical Center
Strategic Timing of Antiretroviral Treatment
Toledo : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Oklahoma
Oklahoma City : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Oregon
Pennsylvania
Allentown : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Philadelphia : Drexel University School of Medicine
A Randomized, Dose-Ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
Philadelphia : Philadelphia FIGHTS
A Randomized, Dose-Ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
Philadelphia : Drexel University College of Medicine
A Study of HIV-infected Subjects Initiating Anti-HIV Drugs for the First Time
Philadelphia : The Children's Hospital of Philadelphia IMPAACT CRS (6701)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
View More »
Philadelphia : Drexel University College of Medicine
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Philadelphia : Reproductive Research Unit, U of Penn Medical Center
An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
Philadelphia : Hosp. of the Univ. of Pennsylvania CRS (6201)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Philadelphia : University Of Pennsylvania
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Philadelphia : Temple General Internal Medicine
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
Philadelphia : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Philadelphia : Philadelphia FIGHT
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Philadelphia : Philadelphia FIGHT
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Philadelphia : University of Pennsylvania
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Philadelphia : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Philadelphia : Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Philadelphia : Temple University
Strategic Timing of Antiretroviral Treatment
Philadelphia :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
Pittsburgh : Pitt CRS (1001)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Rhode Island
Providence : The Miriam Hospital
A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication
South Carolina
Charleston : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Columbia : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Tennessee
Memphis :
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents
Memphis : St. Jude/UTHSC CRS (6501)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Memphis : St. Jude Children's Research Hospital
Strategic Timing of Antiretroviral Treatment
Texas
Addison : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Arlington : Texas Clinical Research Institute
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Austin : Central Texas Clinical Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Austin : Central Texas Clinical Research
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Austin : Central Texas Clinical Research
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
View More »
Bellaire : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Bellaire : St. Hope Foundation
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Dallas : UT Southwestern Medical Center at Dallas
HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
Dallas : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Dallas : Southwest Infectious Disease Clinical Researach Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Dallas : Southwest Infectious Disease Clinical Research, Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Dallas : Uptown Physicians Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Dallas : Southwest Infectious Disease Clinical Research, Inc.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Dallas : Trinity Health and Wellness Center/AIDS Arms, Inc.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Dallas : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Dallas : Amelia Court Hiv Research Clinic
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Dallas : North Texas Infectious Disease Consultants
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Dallas : UT Southwestern Clinical Research Unit
Strategic Timing of Antiretroviral Treatment
Dallas : UT Southwestern Medical Center
Therapeutic Approaches to HAART-Induced Lipodystrophy
Fort Worth : Tarrant County Infectious Disease Associates
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Fort Worth : Tarrant County Infectious Disease Associates
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Fort Worth : Tarrant County Infectious Disease
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Fort Worth : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Fort Worth : Tarrant County Infectious Disease Associates
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Fort Worth : Tarrant County Infectious Disease Associates
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Fort Worth : University of North Texas Health Science Center
Strategic Timing of Antiretroviral Treatment
Harlingen : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Houston : Therapeutic Concepts, PA
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
Houston : Texas Children's Hosp. CRS (3801)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Houston : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Houston : Houston AIDS Research Team CRS (31473)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Houston : Gordon Crofoot, MD, PA
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Houston : Gordon E. Crofoot MD, PA
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : Therapeutic Concepts PA
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : Gordon Crofoot Md, Pa
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : St. Hope Foundation Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : Therapeutic Concepts, PA
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : Gordon Crofoot MD, PA
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Houston : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Houston : Therapeutic Concepts, PA
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Houston : Baylor College Of Medicine
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Houston : Houston AIDS Research Team CRS
Strategic Timing of Antiretroviral Treatment
Houston : Texas Children's Hospital
Strategic Timing of Antiretroviral Treatment
Houston :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
Houston : The University of Texas Health Science Center at Houston
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Longview : Dcol Center For Clinical Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Longview : DCOL Center for Clinical Research
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Longview : DCOL Center for Clinical Research
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
San Antonio : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
San Antonio : Alamo Medical Research
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Antonio : San Antonio Military Health System
Strategic Timing of Antiretroviral Treatment
Virginia
Annandale : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Annandale : Clinical Alliance for Research & Education - Infectious Disease
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Annandale : Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Annandale : CARE-ID
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Danville : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
View More »
Lynchburg : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Richmond : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Richmond : Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Richmond : Virginia Commonwealth University
Strategic Timing of Antiretroviral Treatment
Washington
Seattle : Seattle Children's Hospital NICHD CRS (5017)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Seattle : University of Washington NICHD CRS (5029)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Seattle : Harborview Medical Center NICHD CRS (5027)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Seattle : University of Washington AIDS CRS (1401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Seattle : Peter Shalit, M.D.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
View More »
Seattle : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
West Virginia
Huntington : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Wisconsin
Madison : University of Wisconsin Hospital and Clinics
A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease
Madison : University of Wisconsin Hospital and Clinics
Nelfinavir and M8 Drug-Level Monitoring in HIV-1 Infection
Milwaukee : AIDS Resource Center of Wisconsin
Strategic Timing of Antiretroviral Treatment
Milwaukee : Medical College of Wisconsin
Strategic Timing of Antiretroviral Treatment
Argentina
Buenos Aires : Hospital General de Agudos Buenos Aires Argentina NICHD CRS (5082)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Buenos Aires : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Buenos Aires : FUNCEI
Strategic Timing of Antiretroviral Treatment
Buenos Aires : Fundacion IDEAA
Strategic Timing of Antiretroviral Treatment
Buenos Aires : Hospital General de Agudos JM Ramos Mejia
Strategic Timing of Antiretroviral Treatment
View More »
Buenos Aires : Hospital General de Agudos 'Dr. Teodoro Alvarez'
Strategic Timing of Antiretroviral Treatment
Buenos Aires : Hospital Italiano de Buenos Aires
Strategic Timing of Antiretroviral Treatment
Buenos Aires, Bs As : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Buenos Aires, Bs As : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
C 1249 Abp - Buenos Aires :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Ciudad De Buenos Aires : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Cordoba : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Cordoba : Hospital Rawson
Strategic Timing of Antiretroviral Treatment
El Palomar : Hospital Nacional Profesor Alejandro Posadas
Strategic Timing of Antiretroviral Treatment
La Matanza : Hospital Interzonal General de Agudos Dr. Diego Paroissien
Strategic Timing of Antiretroviral Treatment
Neuquen : CEIN
Strategic Timing of Antiretroviral Treatment
Prov De Santa Fe : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Rosario : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Rosario : Instituto CAICI
Strategic Timing of Antiretroviral Treatment
Australia
Adelaide : Royal Adelaide Hospital
Strategic Timing of Antiretroviral Treatment
Brisbane : Sexual Health and HIV Service - Clinic 2
Strategic Timing of Antiretroviral Treatment
Burwood : Burwood Road General Practice
Strategic Timing of Antiretroviral Treatment
Cairns :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Darlinghurst :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
View More »
Darlinghurst : Holdsworth House Medical Practice
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Darlinghurst : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Darlinghurst : Local Institution
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Darlinghurst : East Sydney Doctors
Strategic Timing of Antiretroviral Treatment
Darlinghurst : Holdsworth House Medical Practice
Strategic Timing of Antiretroviral Treatment
Darlinghurst : St. Vincent's Hospital
Strategic Timing of Antiretroviral Treatment
Darlinghurst : Taylor Square Private Clinic
Strategic Timing of Antiretroviral Treatment
Darlinghurst Nsw : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Melbourne : The Alfred Hospital
A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients
Melbourne :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Melbourne : The Alfred Hospital
HIV-HBV Co-Infection and Liver Disease
Melbourne : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Melbourne : Melbourne Sexual Health Centre
Strategic Timing of Antiretroviral Treatment
Melbourne : Prahran Market Clinic
Strategic Timing of Antiretroviral Treatment
Melbourne : The Alfred Hospital
Strategic Timing of Antiretroviral Treatment
Perth : Royal Perth Hospital
Strategic Timing of Antiretroviral Treatment
South Yarra : Prahran Market Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
St Kilda : Centre Clinic
Strategic Timing of Antiretroviral Treatment
Sydney : 407 Doctors
Once Daily 3TC, Efavirenz and ddI for HIV Infection
Sydney : East Sydney Doctors
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Westmead : Westmead Hospital
Strategic Timing of Antiretroviral Treatment
Austria
Graz : Boehringer Ingelheim Investigational Site 6
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Innsbruck : Innsbruck Medical University
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Innsbruck : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Salzburg : Boehringer Ingelheim Investigational Site 5
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Salzburg : Univ.-Kklinik fuer Innere Medizin III
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
View More »
Vienna : Boehringer Ingelheim Investigational Site 2
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Vienna : Boehringer Ingelheim Investigational Site 3
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Vienna : Boehringer Ingelheim Investigational Site 1
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Vienna : Medical University of Vienna
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Vienna : Otto-Wagner-Spital SMZ /Baumgartner Hoehe
Strategic Timing of Antiretroviral Treatment
Vienna : University Vienna General Hospital
Strategic Timing of Antiretroviral Treatment
Wels : Boehringer Ingelheim Investigational Site 4
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Wien : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Wien : Medical University of Vienna
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Wien : Otto Wagner Spital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Wien : Otto-Wagner-Spital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Wien : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Belgium
Antwerp : Institute of Tropical Medicine
Strategic Timing of Antiretroviral Treatment
Antwerp : Site Reference ID/Investigator# 27827
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Antwerpen : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Antwerpen : SEAMEO Regional Centre for Tropical Medicine
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Antwerpen : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
View More »
Antwerpen : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Antwerpen : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Brussel : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Brussels : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Brussels : Saint-Pierre University Hospital; Department of Infectious Diseases
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Brussels : UCL Saint Luc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Brussels : Hospital St Pierre
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Brussels : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Brussels : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Brussels : Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre)
Strategic Timing of Antiretroviral Treatment
Brussels : Site Reference ID/Investigator# 6129
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Bruxelles : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Bruxelles : Hôpitaux IRIS Sud
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Bruxelles : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Charleroi : Site Reference ID/Investigator# 27825
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Charleroi : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Gent : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Gent : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Ghent : University Hospital Ghent
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Ghent : Universitaire Ziekenhuizen Gent
Strategic Timing of Antiretroviral Treatment
Ghent : Site Reference ID/Investigator# 27823
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Leuven : University Hospital of Leuven
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Leuven : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Leuven : Universitair Ziekenhuis Gasthuisberg
Strategic Timing of Antiretroviral Treatment
Leuven : Site Reference ID/Investigator# 27822
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Leuven : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Liege : CHU Sart Tilman
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Liege : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Liege : Site Reference ID/Investigator# 27824
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Liege : Site Reference ID/Investigator# 27826
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Liège : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Botswana
Gaborone : Gaborone Prevention/Treatment Trials CRS (12701)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Brazil
Belo Horizonte : SOM Federal University Minas Gerais Brazil NICHD CRS (5073)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Campinas :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Campinas : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Porto Alegre : Hospital Nossa Senhora da Conceicao CRS (12201)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Porto Alegre : Hospital Santa Casa NICHD CRS (5098)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
View More »
Porto Alegre : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Recife : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Ribeirao Preto : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Ribeirao Preto :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Rio de Janeiro : Universidade Federal do Rio de Janeiro NICHD CRS (5071)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Rio de Janeiro : Hospital Geral De Nova Igaucu Brazil NICHD CRS (5097)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Rio de Janeiro : Hospital dos Servidores Rio de Janeiro NICHD CRS (5072)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Rio De Janeiro :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Rio de Janeiro : Instituto de Pesquisa Clinica Evandro Chagas (IPEC)
An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
Rio de Janeiro : Hospital Escola Sao Francisco de Assis - UFRJ
Strategic Timing of Antiretroviral Treatment
Rio de Janeiro : Ipec/Fiocruz
Strategic Timing of Antiretroviral Treatment
Rio De Janeiro :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Salvador : SEI - Servicos Especializados em Infectologia
Strategic Timing of Antiretroviral Treatment
Santo André :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Sao Paolo : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Sao Paulo : Insituto de Infectologia Emilio Ribas NICHD CRS (5075)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Sao Paulo : Univ of Sao Paulo Brazil NICHD CRS (5074)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Sao Paulo :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Sao Paulo : Instituto de Infectologia Emilio Ribas - IIER
Strategic Timing of Antiretroviral Treatment
Sao Paulo : Lim 56/Hcfmusp
Strategic Timing of Antiretroviral Treatment
Sao Paulo : Centro de Referencia e Treinamento DST/Aids
Strategic Timing of Antiretroviral Treatment
São Paulo : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Vitoria : University of Espirito Santo
An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
Vitoria : Center for Infectious Diseases at the UFES
Strategic Timing of Antiretroviral Treatment
Burkina Faso
Bobo Dioulasso : Day Hospital, CHU Sanou Souro
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Cameroon
Yaounde : Day Hospital, Central Hospital
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Canada
Edmonton : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Halifax : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Montreal : Clinique Medicale Du Quartier Latin
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Montreal : Clinique Medicale Du Quartier Latin
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Montreal : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
View More »
Montreal : Site Ref # / Investigator 75442
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
Montreal : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Montreal : Local Institution
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Montreal : Immunodeficiency Service Montreal Chest Institute McGill University Health Centre
Trial of Citalopram for the Prevention of Depression
Montréal : Clinique médicale l'Actuel
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Montréal : Clinique Médical du Quartier Latin
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Montréal : Montreal Chest Institute, Immunodeficiency Dept.
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Ottawa : Site Ref # / Investigator 77613
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
Ottawa : The Ottawa Hospital
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Toronto : Maple Leaf Medical Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Toronto : Sunnybrook Health Sciences Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Toronto : Sunnybrook Health Sciences Centre
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Toronto : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Toronto : Site Ref # / Investigator 79793
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
Vancouver : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Vancouver : Site Ref # / Investigator 75438
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
Vancouver : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Victoria : Site Ref # / Investigator 75440
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
Victoria : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Chile
Santiago : Fundacion Arriaran
Strategic Timing of Antiretroviral Treatment
China
Beijing : Division of Treatment and Care, NCAIDS, China CDC
A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance
Colombia
Bogota : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Czech Republic
Denmark
Aarhus : Department of Infectious Diseases, Aarhus University Hospital
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
Aarhus : Arhus Universitetshospital, Skejby
Strategic Timing of Antiretroviral Treatment
Copenhagen : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Copenhagen : Rigshospitalet, Department of Infectious Diseases, M5112 CRS
Strategic Timing of Antiretroviral Treatment
Hvidovre : Hvidovre University Hospital, Department of Infectious Diseases CRS
Strategic Timing of Antiretroviral Treatment
View More »
Hvidovre N/A : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Odense : Odense University Hospital
Strategic Timing of Antiretroviral Treatment
Estonia
Finland
France
Besancon : CHU de Besancon - Hopital Saint-Jacques
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Besancon : CHU de BESANCON - Hopital Saint Jacques
Strategic Timing of Antiretroviral Treatment
Besançon : CHU de Besancon, Hopital Saint-Jacques
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Bobigny : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Bondy : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
View More »
Bondy Cedex : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Bordeaux : CHU de Bordeaux
Efficacy and Safety of Varenicline Among HIV-infected Patients
Bordeaux : Groupe Hospitalier Pellegrin
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Bordeaux : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Caen : CHU De Caen, Service de Néphrologie Hémodialyse
Renal Transplantation and Raltegravir in HIV-Infected Patients
Caen : CHU Cote de Nacre
Strategic Timing of Antiretroviral Treatment
Clamart : Valerie Martinez
Lenalidomide in Kaposi Disease Associated With HIV Infection
Clamart : Hopital Antoine Beclere
Strategic Timing of Antiretroviral Treatment
Creteil : Hôpital Henri Mondor
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
Creteil : Hopital Henri Mondor
Strategic Timing of Antiretroviral Treatment
Créteil : Hôpital Henri Mondor, Service de Néphrologie Transplantation
Renal Transplantation and Raltegravir in HIV-Infected Patients
Dijon : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Garches : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Kremlin Bicêtre : Hôpital Kremlin Bicêtre, Service de Néphrologie
Renal Transplantation and Raltegravir in HIV-Infected Patients
Le Kremlin-Bicetre : Hopital de Bicetre
Strategic Timing of Antiretroviral Treatment
Lyon : Hôpital de la Croix-Rousse
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
LYON Cedex 4 : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Marseille :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Marseille : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Marseille Cedex 09 : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Montpellier : CHU Hôpital Gui de Chauliac
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Montpellier Cedex 5 : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Nice :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Nice : Archet 1 Chu Nice Department of Infectology
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Nice N/A :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Paris : Hôpital Pitié Salpétrière
Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Paris : Hopital Bichat Claude Bernard
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Paris : Hopital Saint Antoine
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Paris : Hopital Saint Louis
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Paris : Saint-Louis Hospital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Paris : Hôpital Bichat-Claude Bernard
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Paris : hôpital Tenon
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Paris : Hopital Saint Antoine
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Paris : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Paris : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Paris : Hopital Hotel Dieu
Strategic Timing of Antiretroviral Treatment
Paris : Hopital Europeen Georges Pompidou
Strategic Timing of Antiretroviral Treatment
Paris : Hopital Saint-Louis
Strategic Timing of Antiretroviral Treatment
Paris : Hopital Saint-Antoine
Strategic Timing of Antiretroviral Treatment
Paris : Groupe Hospitalier Pitie-Salpetriere
Strategic Timing of Antiretroviral Treatment
Paris : Hopital Cochin CIC de vaccinologie
Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients
Paris : Hôpital Bichat-Claude Bernard
Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
Paris Cedex 10 : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Paris Cedex 10 : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Paris Cedex 12 : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Paris Cedex 12 :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Paris Cedex 12 : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Paris Cedex 13 : Maladies Infectieuses Dpt
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Paris CEDEX 14 : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Paris cedex 15 : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Paris, 75 : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Pessac : Hôpital Haut Lévêque
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Pessac : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Pessac Cedex : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Rennes : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Suresnes : Hopital Foch
Strategic Timing of Antiretroviral Treatment
Toulon : Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Service d'infectiologie
IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients
Toulon : Centre Hospitalier Intercommunal de Toulon La Seyne sur mer
IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients
Tourcoing : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Tourcoing : Hopital Gustave Dron
Strategic Timing of Antiretroviral Treatment
Germany
Aachen : Site Reference ID/Investigator# 28228
Kaletra in Combination With Integrase Inhibitors
Aachen : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Aachen : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Aachen : Site Reference ID/Investigator# 28521
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
View More »
Berlin : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Berlin :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Berlin : Site Reference ID/Investigator# 28229
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28249
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28260
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 30764
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 47155
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Ref # / Investigator 63682
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28185
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28199
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28243
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28183
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28205
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 30762
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 30763
Kaletra in Combination With Integrase Inhibitors
Berlin : CHARITÉ Berlin
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Berlin : EPIMED GmbH
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Berlin : MIB Dienstleistung GmbH
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Berlin : Epimed GmbH
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Berlin : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Berlin : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Berlin : EPIMED-Gesellschaft fuer epidemiologische und klinische Forschung in der MedizinmbH
Strategic Timing of Antiretroviral Treatment
Berlin : Gemeinschaftspraxis Jessen-Jessen-Stein
Strategic Timing of Antiretroviral Treatment
Berlin : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Berlin : Site Reference ID/Investigator# 28484
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28485
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28486
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28496
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28503
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 47146
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28567
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 32383
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 32384
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28514
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28522
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28557
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 29154
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28494
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28504
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28518
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28559
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28569
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 29147
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 59472
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 29271
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Berlin : Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Berlin : EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Bochum : Site Reference ID/Investigator# 28488
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Bonn : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Bonn :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Bonn : University of Bonn
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Bonn : Medizinische Universitätsklinik
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Bonn : University of Bonn
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Bonn : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Bonn : Medizinische Universitaetsklinik - Bonn, Immunologische Ambulanz CRS
Strategic Timing of Antiretroviral Treatment
Bonn : Site Reference ID/Investigator# 28562
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Bonn : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Bremen : Site Reference ID/Investigator# 28224
Kaletra in Combination With Integrase Inhibitors
Bremen : Site Reference ID/Investigator# 29269
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Bremen : Site Reference ID/Investigator# 59469
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Cologne : Site Reference ID/Investigator# 28252
Kaletra in Combination With Integrase Inhibitors
Cologne : University of Cologne
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Cologne : Klinik I fur Innere Medizin der Universitat zu Koeln, Studienbuero fuer Infektiologie u. HIV CRS
Strategic Timing of Antiretroviral Treatment
Cologne : Site Reference ID/Investigator# 29262
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Cologne : Site Reference ID/Investigator# 28571
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Cologne : Site Reference ID/Investigator# 28563
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Cologne : Site Reference ID/Investigator# 28554
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Cologne : Site Reference ID/Investigator# 28495
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Dortmund :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Dortmund : Site Reference ID/Investigator# 28184
Kaletra in Combination With Integrase Inhibitors
Dortmund : Site Ref # / Investigator 28223
Kaletra in Combination With Integrase Inhibitors
Dortmund : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Dortmund : Klinikum Dortmund gGmbH
Strategic Timing of Antiretroviral Treatment
Dortmund : Site Reference ID/Investigator# 28516
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Dortmund : Site Reference ID/Investigator# 47142
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Dortmund : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Dresden :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Dresden : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Duesseldorf : Site Ref # / Investigator 63685
Kaletra in Combination With Integrase Inhibitors
Duesseldorf : Site Ref # / Investigator 28188
Kaletra in Combination With Integrase Inhibitors
Duesseldorf : Site Reference ID/Investigator# 28250
Kaletra in Combination With Integrase Inhibitors
Duesseldorf : Universitaetsklinikum Duesseldorf
Strategic Timing of Antiretroviral Treatment
Duesseldorf : Site Reference ID/Investigator# 28547
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Duesseldorf : Site Reference ID/Investigator# 28491
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Duisburg : Site Reference ID/Investigator# 28231
Kaletra in Combination With Integrase Inhibitors
Duisburg : Site Reference ID/Investigator# 28524
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Dusseldorf : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Erlangen :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Erlangen : Universitaetsklinikum Erlangen
Strategic Timing of Antiretroviral Treatment
Essen : Site Reference ID/Investigator# 28194
Kaletra in Combination With Integrase Inhibitors
Essen : Universitätsklinikum Essen, Dermatologie, HIV Ambulanz
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Essen : Klinik fur Dermatologie, Venerologie, Allergologie
Strategic Timing of Antiretroviral Treatment
Frankfurt : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Frankfurt :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Frankfurt : Site Reference ID/Investigator# 28233
Kaletra in Combination With Integrase Inhibitors
Frankfurt : Site Reference ID/Investigator# 28227
Kaletra in Combination With Integrase Inhibitors
Frankfurt : Infektiologikum
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Frankfurt : Johann Wolfgang Goethe-University Hospital / Infectious Diseases Hs 68
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Frankfurt : German Competence Network
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Frankfurt : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Frankfurt : Johann Wolfgang Goethe - University Hospital, Infektionsambulanz CRS
Strategic Timing of Antiretroviral Treatment
Frankfurt : Site Reference ID/Investigator# 28545
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Frankfurt : Site Reference ID/Investigator# 28520
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Frankfurt : Site Reference ID/Investigator# 29270
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Frankfurt : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Frankfurt am Main : Site Ref # / Investigator 54202
Kaletra in Combination With Integrase Inhibitors
Frankfurt am Main : Johann Wolfgang Goethe-Universität
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Frankfurt am Main : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Frankfurt Am Main : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Frankfurt am Main : Site Reference ID/Investigator# 29260
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Freiburg :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Freiburg : Site Reference ID/Investigator# 28258
Kaletra in Combination With Integrase Inhibitors
Freiburg : Site Reference ID/Investigator# 28246
Kaletra in Combination With Integrase Inhibitors
Freiburg : Universitatsklinikum Freiburg
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Freiburg : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Freiburg : Site Reference ID/Investigator# 29266
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Freiburg : Site Reference ID/Investigator# 28550
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Freiburg : Site Reference ID/Investigator# 28564
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Fuerth : Site Reference ID/Investigator# 28251
Kaletra in Combination With Integrase Inhibitors
Fuerth : Site Reference ID/Investigator# 28570
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Giessen : Site Reference ID/Investigator# 28193
Kaletra in Combination With Integrase Inhibitors
Giessen : Site Reference ID/Investigator# 28196
Kaletra in Combination With Integrase Inhibitors
Giessen : Site Reference ID/Investigator# 28498
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Halle : Site Reference ID/Investigator# 28261
Kaletra in Combination With Integrase Inhibitors
Hamburg : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Hamburg :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Hamburg : Site Reference ID/Investigator# 47154
Kaletra in Combination With Integrase Inhibitors
Hamburg : Site Reference ID/Investigator# 28256
Kaletra in Combination With Integrase Inhibitors
Hamburg : Site Reference ID/Investigator# 28202
Kaletra in Combination With Integrase Inhibitors
Hamburg : Site Reference ID/Investigator# 28259
Kaletra in Combination With Integrase Inhibitors
Hamburg : ICH Study Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Hamburg : Universitätsklinikum Hamburg-Eppendorf, Ambulanzzentrum des UKE GmbH, Bereich Infektiologie
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Hamburg : ICH Study Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Hamburg : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Hamburg : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Hamburg : ICH Study Center
Strategic Timing of Antiretroviral Treatment
Hamburg : Ifi - Studien und Projekte GmbH
Strategic Timing of Antiretroviral Treatment
Hamburg : University Medical Centre Hamburg-Eppendorf
Strategic Timing of Antiretroviral Treatment
Hamburg : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Hamburg : Site Reference ID/Investigator# 28507
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 29272
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 32386
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28544
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28513
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 29267
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28566
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28489
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28515
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28549
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 29261
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 32382
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hannover : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Hannover : Site Reference ID/Investigator# 28248
Kaletra in Combination With Integrase Inhibitors
Hannover : Medizinische Hochschule Hannover
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Hannover : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Hannover : Site Reference ID/Investigator# 28568
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hannover : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Hanover : Site Reference ID/Investigator# 28230
Kaletra in Combination With Integrase Inhibitors
Hanover : Medizinische Hochschule Hannover
Strategic Timing of Antiretroviral Treatment
Hanover : Site Reference ID/Investigator# 28523
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hanover : Site Reference ID/Investigator# 29273
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Heidelberg : Universitaetsklinikum Heidelberg
Strategic Timing of Antiretroviral Treatment
Heidelberg : Site Reference ID/Investigator# 47145
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Karlsruhe : Site Reference ID/Investigator# 28551
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Koblenz : Site Reference ID/Investigator# 47153
Kaletra in Combination With Integrase Inhibitors
Koblenz : Site Reference ID/Investigator# 28561
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Koeln : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Koln : Infektlonsambulanz Unlkllnik Koln
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Köln : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Köln :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Köln : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Krefeld : Site Reference ID/Investigator# 18221
Kaletra in Combination With Integrase Inhibitors
Krefeld : Site Reference ID/Investigator# 28483
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Leipzig : Site Reference ID/Investigator# 47144
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Leipzig : Site Reference ID/Investigator# 28482
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Ludwigshafen : Site Reference ID/Investigator# 47151
Kaletra in Combination With Integrase Inhibitors
Ludwigshafen : Site Reference ID/Investigator# 28493
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Luebeck : Site Ref # / Investigator 28192
Kaletra in Combination With Integrase Inhibitors
Luebeck : Site Reference ID/Investigator# 28500
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Madgeburg : Site Reference ID/Investigator# 59468
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Magdeburg :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Magdeburg : Site Ref # / Investigator 54278
Kaletra in Combination With Integrase Inhibitors
Mainz :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Mainz : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Mainz : Site Reference ID/Investigator# 28565
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Mainz : Site Reference ID/Investigator# 28574
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Mannheim :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Mannheim : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Muenchen : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Muenster : Site Reference ID/Investigator# 28197
Kaletra in Combination With Integrase Inhibitors
Muenster : Site Reference ID/Investigator# 28492
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Muenster : Site Reference ID/Investigator# 28560
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Muenster : Site Reference ID/Investigator# 28490
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munchen : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Munchen : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
München :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
München : University München
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
München : MUC Research GmbH
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Munich : Site Reference ID/Investigator# 28225
Kaletra in Combination With Integrase Inhibitors
Munich : Site Reference ID/Investigator# 28235
Kaletra in Combination With Integrase Inhibitors
Munich : Site Reference ID/Investigator# 28242
Kaletra in Combination With Integrase Inhibitors
Munich : Site Reference ID/Investigator# 28200
Kaletra in Combination With Integrase Inhibitors
Munich : Infektionsambulanz, Med Poliklink, Klinikum der Universitat Munchnen
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Munich : Klinikum der Universitaet Muenchen
Strategic Timing of Antiretroviral Treatment
Munich : Site Reference ID/Investigator# 28508
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28517
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28556
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28505
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28519
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28548
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Nuremberg : Site Ref # / Investigator 81614
Kaletra in Combination With Integrase Inhibitors
Nuremberg : Site Reference ID/Investigator# 5346
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Oldenburg : Site Reference ID/Investigator# 28555
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Osnabrueck : Site Reference ID/Investigator# 28240
Kaletra in Combination With Integrase Inhibitors
Osnabrueck : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Osnabrueck : Site Reference ID/Investigator# 28553
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Regensburg :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Regensburg : Site Reference ID/Investigator# 47149
Kaletra in Combination With Integrase Inhibitors
Regensburg : University Clinic Regensburg, Klinik I Fuer Innere Medizin
Strategic Timing of Antiretroviral Treatment
Regensburg : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Rostok : Site Reference ID/Investigator# 59467
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Saarbruecken : Site Reference ID/Investigator# 28506
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Schkeuditz : Site Ref # / Investigator 63686
Kaletra in Combination With Integrase Inhibitors
Schkeuditz : Site Reference ID/Investigator# 59471
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Stuttgart :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Stuttgart : Site Reference ID/Investigator# 28239
Kaletra in Combination With Integrase Inhibitors
Stuttgart : Site Reference ID/Investigator# 28257
Kaletra in Combination With Integrase Inhibitors
Stuttgart : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Stuttgart : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Stuttgart : Site Reference ID/Investigator# 29265
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Stuttgart : Site Reference ID/Investigator# 28552
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Stuttgart : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Troisdorf : Site Reference ID/Investigator# 28572
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Tübingen : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Tuebingen : Site Reference ID/Investigator# 28511
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Ulm :
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Wiesbaden : Site Reference ID/Investigator# 29264
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Wuerzburg : University of Wuerzburg, Medizinische Poliklinik, Schwerpunkt Hepatologie/Infektologie CRS
Strategic Timing of Antiretroviral Treatment
Wuppertal : Site Ref # / Investigator 28234
Kaletra in Combination With Integrase Inhibitors
Wuppertal : Site Reference ID/Investigator# 28546
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Greece
Athens : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Athens : Korgialenio-Benakio Hellenic Red Cross
Strategic Timing of Antiretroviral Treatment
Athens : Syngros Hospital
Strategic Timing of Antiretroviral Treatment
Athens : Evangelismos General Hospital
Strategic Timing of Antiretroviral Treatment
Athens : Hippokration University General Hospital of Athens
Strategic Timing of Antiretroviral Treatment
View More »
Athens : Attikon University General Hospital
Strategic Timing of Antiretroviral Treatment
Patras : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Piraeus : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Thessaloniki : AHEPA University Hospital
Strategic Timing of Antiretroviral Treatment
Hungary
Budapest : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Budapest : Updated
Telaprevir Open-Label Study in Co-Infected Patients
India
Chennai : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Chennai : YRGCARE Medical Centre VHS, Chennai CRS
Strategic Timing of Antiretroviral Treatment
Kolkata : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Mangalore :
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents
Mumbai : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
View More »
Pune : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Pune : Institute of Infectious Diseases
Strategic Timing of Antiretroviral Treatment
Ireland
Dublin : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Dublin : Mater Hospital and UCD
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Dublin : St James's Hospital Dublin
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Dublin : Mater Misericordiae University Hospital
Strategic Timing of Antiretroviral Treatment
Dublin 9 : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
View More »
Galway : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Israel
Beer Sheva : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Beer-Sheva : Site Reference ID/Investigator# 27833
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Haifa : Rambam Medical Center
Strategic Timing of Antiretroviral Treatment
Haifa : Site Reference ID/Investigator# 17549
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Jerusalem : Site Reference ID/Investigator# 27830
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
View More »
Kfar Saba : Site Reference ID/Investigator# 27832
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Ramat-Gan : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Rehovot : Site Reference ID/Investigator# 27829
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Tel Aviv : Tel Aviv Sourasky Medical Center
Strategic Timing of Antiretroviral Treatment
Tel-Aviv : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Tel-Hashomer : Site Reference ID/Investigator# 27831
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Italy
Bari : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Bergamo : Ospedali Riuniti
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Bologna : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Brescia : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Busto Arsizio (Va) : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
View More »
Busto Arsizio/Varese : Azienda Ospedaliera Ospedale di Circolo Busto Arsizio
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Firenze : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Florence : Italian Register for HIV-infection in Children
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Genova : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Milan : Infectious Diseases Department Fondazione Centro San Raffaele
Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression
Milan : San Raffaele Hospital Dep. Infectious Diseases
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy
Milan : San Raffaele Hospital, Dep. Infectious Diseases
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
Milan : Ospedale San Raffaele S.r.l.
Strategic Timing of Antiretroviral Treatment
Milano : Ospedale Luigi Sacco
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Milano : Fondazione Centro San Raffaele del Monte Tabor
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Milano : Clinic of Infectious Diseases, University of Milan-San Paolo Hospital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Milano : Ospedale Luigi Sacco
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Milano : Fondazione Centro San Raffaele
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Milano : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Milano : Istituto San Raffaele
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
Milano : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Modena : Policlinico di Modena, Divisione di Malattie Infettive
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Modena : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Modena : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Monza : Azienda Ospedaliera San Gerardo, Divisione di Malattie Infettive
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Napoli : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Padova : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Palermo : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Pavia : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Pescara : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Roma : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Roma : Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Roma : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Rome : IFO - S. Gallicano, Dermatologia Infettiva
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Rome : IRCSS
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Rome : Policlinico Universitario Agostino Gemelli
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Rome : National Institute for Infectious Diseases "L. Spallanzani"
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Rome : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Rome : Lazzaro Spallanzani IRCSS
Strategic Timing of Antiretroviral Treatment
Torino : University of Torino, Dept of Infectious Disease
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Torino : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Torino : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Varese : Ospedale di Circolo and Fondazione Macchi
Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
Japan
Fukuoka : Site Ref # / Investigator 57629
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Hiroshima : Site Ref # / Investigator 57630
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Hokkaido : Site Ref # / Investigator 57631
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Kitakyushu : Site Ref # / Investigator 57628
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Kurashiki : Site Ref # / Investigator 57638
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
View More »
Kyoto : Site Ref # / Investigator 57634
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Miyagi : Site Ref # / Investigator 57636
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Nagoya : Site Ref # / Investigator 57625
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Nagoya : Site Ref # / Investigator 57626
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Niigata : Site Ref # / Investigator 57637
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Nishinomiya : Site Ref # / Investigator 57632
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Osaka : Site Ref # / Investigator 57639
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Osaka : Site Ref # / Investigator 57640
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57641
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57643
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57646
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57647
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57648
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57644
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57645
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57650
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 48722
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Yokohama : Site Ref # / Investigator 57633
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Korea, Republic of
Dae-Gu : Updated
A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista
Incheon : GSK Investigational Site
ZIAGEN® Post-marketing Surveillance
Seoul : Seoul National University Hospital
Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
Seoul : MSD Korea Ltd.
Stocrin Re-examination Study (0831-028 AM1)
Luxembourg
Luxembourg : Centre Hospitalier de Luxembourg
Strategic Timing of Antiretroviral Treatment
Luxembourg : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Malawi
Blantyre : College of Med. JHU CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Lilongwe : University of North Carolina Lilongwe CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Malaysia
Mali
Bamako : Serefo/Cesac Mali
Strategic Timing of Antiretroviral Treatment
Mexico
Df : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Distrito Federal : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Guadalajara : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Tlalpan : INCMNSZ
Strategic Timing of Antiretroviral Treatment
Morocco
Netherlands
Amsterdam : Academic Medical Center
Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)
Nijmegen : Radboud University Nijmegen Medical Centre
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Rotterdam : Erasmus Medical Center
Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)
Rotterdam : Erasmus Medical Center Rotterdam
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Utrecht : University Medical Center Utrecht
RAltegravir Switch STudy: Effects on Endothelial Recovery
Nigeria
Norway
Oslo : Oslo University Hospital, Ullevål
Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
Oslo : Oslo University Hospital, Ulleval
Strategic Timing of Antiretroviral Treatment
Peru
Barranco : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Cercado : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Iquitos : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Jesus Maria : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
La Victoria : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
View More »
Lima : Asociacion Civil Impacta Salud y Educacion
Strategic Timing of Antiretroviral Treatment
Lima : IMPACTA San Miguel
Strategic Timing of Antiretroviral Treatment
Lima : Hospital Nacional Edgardo Rebagliati Martins
Strategic Timing of Antiretroviral Treatment
Lima : Hospital Nacional Guillermo Almenara Irigoyen
Strategic Timing of Antiretroviral Treatment
Lima : Via Libre
Strategic Timing of Antiretroviral Treatment
San Miguel : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Poland
Bialystok : Wojewodzki Szpital Specjalistyczny
Strategic Timing of Antiretroviral Treatment
Bydgoszcz :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Myslowice :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Warsaw : Wojewodzki Szpital Zakazny
Strategic Timing of Antiretroviral Treatment
Warszawa : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
View More »
Warszawa :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Wroclaw : EMC Instytut Medyczny SA
Strategic Timing of Antiretroviral Treatment
Zielona Góra :
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
Portugal
Aveiro : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Barreiro : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Faro : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Lisboa : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Lisboa : Hospital de Santa Maria - CHLN EPE
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
View More »
Lisboa : Hospital Santo Antonio Dos Capuchos, Centro Hospitalar de Lisboa
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Lisboa : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Lisboa : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Lisboa N/A : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Lisbon : Hospital de Santa Maria-CHLN, EPE
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Lisbon : Hospital de Santa Maria
Strategic Timing of Antiretroviral Treatment
Lisbon : Hospital Curry Cabral
Strategic Timing of Antiretroviral Treatment
Lisbon : Hospital de Egas Moniz
Strategic Timing of Antiretroviral Treatment
Oporto : Hospital Joaquim Urbano
Strategic Timing of Antiretroviral Treatment
Porto : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Porto : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Porto : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Pragal : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Santarem : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Sao Martinho do Bispo : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Vila Nova de Gaia : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Puerto Rico
Ponce : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Rio Piedras : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Rio Piedras : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Rio Piedras : San Juan Hospital
Strategic Timing of Antiretroviral Treatment
San Juan : San Juan City Hosp. PR NICHD CRS (5031)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
View More »
San Juan : University of Puerto Rico Pediatric HIV/AIDS CRS (6601)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
San Juan : Puerto Rico-AIDS CRS (5401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
San Juan : Fundacion de Investigacion de Diego
Drug Interaction Study of PSI-7977 and Antiretroviral Therapy(ART) Combinations in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients.
San Juan : Clinical Research Puerto Rico Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Juan : Clinical Research Puert Rico
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Juan : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
San Juan : Clinical Research Puerto Rico
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
San Juan : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Juan : Puerto Rico-AIDS Clinical Trials Unit (PR-ACTU)
Strategic Timing of Antiretroviral Treatment
San Juan : University of Puerto Rico Pediatric Research Site
Strategic Timing of Antiretroviral Treatment
San Juan :
Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects
San Juan Pr :
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Romania
Brasov : Boehringer Ingelheim Investigational Site 56
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Brasov : Boehringer Ingelheim Investigational Site 57
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Brasov : Boehringer Ingelheim Investigational Site 58
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucharest : Victor Babes Hospital
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Bucuresti : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
View More »
Bucuresti : Boehringer Ingelheim Investigational Site 29
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 30
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 31
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 32
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 34
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 35
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 36
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 38
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 41
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 42
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 43
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 40
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 33
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 37
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 39
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Constanta : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Constanta : Boehringer Ingelheim Investigational Site 51
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Constanta : Boehringer Ingelheim Investigational Site 48
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Constanta : Boehringer Ingelheim Investigational Site 49
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Constanta : Boehringer Ingelheim Investigational Site 50
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Craiova : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Craiova : Boehringer Ingelheim Investigational Site 47
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Craiova : Boehringer Ingelheim Investigational Site 46
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Iasi : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Iasi : Boehringer Ingelheim Investigational Site 53
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Iasi : Boehringer Ingelheim Investigational Site 52
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Iasi : Boehringer Ingelheim Investigational Site 54
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Iasi : Boehringer Ingelheim Investigational Site 55
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Tg.Mures : Boehringer Ingelheim Investigational Site 60
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Tg.Mures : Boehringer Ingelheim Investigational Site 59
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Tg.Mures : Boehringer Ingelheim Investigational Site 61
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Tg.Mures : Boehringer Ingelheim Investigational Site 62
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Timisoara : Boehringer Ingelheim Investigational Site 44
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Timisoara : Boehringer Ingelheim Investigational Site 45
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Russian Federation
Loshkar-Ola : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Moscow : Merck Sharp & Dohme IDEA, Inc.
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With HIV-1
Moscow : Central Research Institute of Epidemiology
Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients
Perm :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Saint Petersburg : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
View More »
Saint-Petersburg :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Saint-Petersburg : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Smolensk :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Smolensk : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Smolensk : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
St Petersburg : Updated
Telaprevir Open-Label Study in Co-Infected Patients
St. Petersburg : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
St. Petersburg : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
St-Petersburg : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Volgograd : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Voronezh :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Senegal
Dakar : Clinical Research and Training Center, Fann Hospital
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
South Africa
Bloemfontein :
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents
Bloemfontein : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Cape Town : Stellenbosch University CRS (8950)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Cape Town : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Cape Town : Desmond Tutu HIV Foundation
Strategic Timing of Antiretroviral Treatment
View More »
Cape Town : Stellenbosch Univ. CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Diepkloof : Perinatal HIV Research UNIT
Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV
Dundee : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Dundee : Updated
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents
Durban : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Durban : DICTU
Strategic Timing of Antiretroviral Treatment
Durban : University KZN
Strategic Timing of Antiretroviral Treatment
Durban : Durban Paediatric HIV CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Ga-Rankuwa : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Gaunteng : Infectious Diseases Clinincal Trial Unit
Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV
Johannesburg : Soweto IMPAACT CRS (8052)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Johannesburg : Harriet Shezi Children's Clinic (8051)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Johannesburg : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Johannesburg : CHRU
Strategic Timing of Antiretroviral Treatment
Johannesburg : Shandukani Research CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Johannesburg, Gauteng : Soweto IMPAACT CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Pretoria :
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents
Pretoria : 1 Military Hospital
Strategic Timing of Antiretroviral Treatment
Umlazi : CAPRISA Umlazi CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Spain
A Coruña : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Alcala de Henares : Hospital Universitario Principe de Asturias
Strategic Timing of Antiretroviral Treatment
Alcalá de Henares : Hospital Príncipe de Asturias
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Alcalá de Henares : Hospital Príncipe de Asturias
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Alicante :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
View More »
Alicante : Hospital General Universitario Alicante
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Alicante : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Alicante : Hospital General de Alicante
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Asturias : H. Universitario Central de Asturias
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Badalona : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Badalona :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Badalona : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Badalona : Hospital Universitari Germans Trias i Pujol, Badalona
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Badalona : Hospital Germans Trias i Pujol
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
Badalona : H. Germans Trias i Pujol
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Badalona : Hospital Universitari Germans Trias I Pujol, HIV Unit and Retrovirology Lab CRS
Strategic Timing of Antiretroviral Treatment
Badalona : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Barcelona : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Barcelona : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Barcelona : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Barcelona : Hospital de la Santa Creu i Sant Pau
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Barcelona : Hospital del Mar
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Barcelona : Hospital clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Barcelona : Hospital Germans Trias I Pujol
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Barcelona : Hospital Universitari Bellvitge HIV Unit. Infectious Disease Service.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Barcelona : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Barcelona : Spanish Perinatal Cohort
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Barcelona : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Barcelona : Unidad de VIH, Hospital de Bellvitge, Calle Feixa Llarga s/n, Hospitalet de Llobregat.
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
Barcelona : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Barcelona : Hospital Vall d'Hebrón
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Barcelona : Hospital Santa Creu i Sant Pau
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Barcelona : Hospital del Mar
Strategic Timing of Antiretroviral Treatment
Barcelona : Hospital de la Santa Creu i Sant Pau
Strategic Timing of Antiretroviral Treatment
Barcelona : Hospital Clinico de Barcelona CRS
Strategic Timing of Antiretroviral Treatment
Barcelona : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Basurto : Hospital de Basurto
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Cadiz : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Cordoba : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Cordoba :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Cordoba : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Cordoba : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Cordoba : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Córdoba : Hospital Reina Sofía
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
El Ferrol : Hospital Arquitecto Marcide
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Elche :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Elche : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Elche : Hospital de Elche
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Esplugues de Llobregat : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Granada : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Granada : Hospital Universitario Virgen de las Nieves Granada; Médico Adjunto del Servicio de Medicina Interna
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Granada : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Granada : Hospital Clínico San Cecilio
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Granada : Hospital Virgen de las Nieves
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Granada : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Granollers : Hospital General de Granollers
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Granollers : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Guadalajara : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Huelva : H. Juan Ramón Jiménez
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Jerez de la Frontera : Hospital de Jerez
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Jerez de la Frontera : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
La Coruña : Hospital Juan Canalejo
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Leganes : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Leganés : Hospital Severo Ochoa
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Logrono : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Logroño : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Logroño : H. San Pedro
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Madrid :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Madrid : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Madrid : Hospital Clínico San Carlos
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Hospital La Paz
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Hospital Doce de Octubre
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Hospital Gregorio Marañón
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Hospital Ramón y Cajal
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Madrid : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Madrid : Hospital General Universitario Gregorio Maranon
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Madrid : Hospital Ramon y Cajal
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Madrid : Hospital La Paz
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Madrid : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Madrid : Madrid Paediatric HIV Cohort
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Madrid : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Madrid : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Madrid : H. Universitario Infanta Leonor
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Hospital Doce de Octubre
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Hospital Gregorio Marañón
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Hospital La Paz
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Hospital Ramón y Cajal
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : H. Clinico San Carlos
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Hospital Carlos III
Strategic Timing of Antiretroviral Treatment
Madrid : Hospital Clinico San Carlos
Strategic Timing of Antiretroviral Treatment
Madrid : Hospital La Paz CRS
Strategic Timing of Antiretroviral Treatment
Madrid : Hospital La Princesa, Internal Medicine and Infectious Disease Service CRS
Strategic Timing of Antiretroviral Treatment
Madrid : Hospital Universitario Doce de Octubre
Strategic Timing of Antiretroviral Treatment
Madrid : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Malaga : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Malaga : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Málaga : Hospital Virgen de la Victoria
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Mallorca : H. Universitario Son Espases
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Marbella : Hospital Costa del Sol
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Marbella : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Mataro : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Mataro : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Mataró : Hospital de Mataró
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Mostoles : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Mostoles, Madrid : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Móstoles, Madrid : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Pamplona : Hospital de Navarra
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
San Sebastian :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
San Sebastian : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
San Sebastián : Hospital Donostia
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Santander : Hospital Marqués de Valdecilla
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Santiago de Compostela : Hospital Clinico Universitario de Santiago
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Santiago de Compostela : Complexo Hospitalario Universitario de Santiago
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Santiago de Compostela : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Sevilla : Hospital Virgen del Rocio
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Sevilla : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Sevilla : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Sevilla : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Sevilla N/A :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Tarragona : Hospital de Santa Tecla
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Tarragona : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Tenerife, Canary Island : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Terrassa : Hospital Universitari Mutua Terrassa
Strategic Timing of Antiretroviral Treatment
Valencia :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Valencia : Hospital La Fe de Valencia
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Valencia : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Valencia : Hospital La Fe
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Valencia : Hospital General Universitario de Valencia
Strategic Timing of Antiretroviral Treatment
Valencia : Hospital Universitario y Politecnico La Fe
Strategic Timing of Antiretroviral Treatment
Valencia : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Vigo : Hospital Xeral Cíes
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Vigo : Complejo Hospitalario Xeral Cies
Strategic Timing of Antiretroviral Treatment
Villajoyosa : Hospital Marina Baixa
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Sweden
Gothenburg : Sahlgrenska University Hospital
Strategic Timing of Antiretroviral Treatment
Malmo : Skane University Hospital
Strategic Timing of Antiretroviral Treatment
Stockholm : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Stockholm :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Switzerland
Bale : Universitätsspital Basel Klinik für Infektiologie & Spitalhygiene
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
Basel : Swiss Mother and Child HIV Cohort
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Basel : University Hospital Basel
Strategic Timing of Antiretroviral Treatment
Bern : Bern University Hospital
Strategic Timing of Antiretroviral Treatment
Berne : Inselspital PKT2B / Poliklinik für Infektiologie
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
View More »
Geneva : Geneva University Hospital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Geneva : HUG /Division des Maladies infectieuses Unité VIH/SIDA
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
Geneva : Unite VIH/SIDA Geneva
Strategic Timing of Antiretroviral Treatment
La Chaux-de-Fonds : Hôpital Neuchâtelois - La Chaux-de-Fonds Service des Maladies infectieuses
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
Lausanne : CHUV / Service des maladies infectieuses Médecine 2
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
Lugano : Ospedale Civico di Lugano
Strategic Timing of Antiretroviral Treatment
St Gallen : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
St Gallen : Kantonsspital / Infektiologie und Spitalhygiene Departement Innere Medizin
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
Zurich : Zentrum fur Infektionskrankheiten
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Zurich : University Hospital of Zurich; Division of Infectious Diseases and Hospital Epidemiology
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Zurich : Universitätsspital Zürich Division of Infectious Diseases and Hospital Epidemiology Department of Internal Medicine
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
Zurich : University Hospital Zurich
Raltegravir in the Swiss HIV Cohort Study
Zurich : University Hospital Zurich
Strategic Timing of Antiretroviral Treatment
Tanzania
IDC Research Offices : Kilimanjaro Christian Medical CRS (12901)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Thailand
Bangkok :
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents
Bangkok : Siriraj Hospital Mahidol University CRS (8251)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Bangkok : Bhumibol Adulyadej Hospital (8355)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Bangkok : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Bangkok : Thai Red Cross AIDS Research Centre
Antiretroviral Therapy for Acute HIV Infection
View More »
Bangkok : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Bangkok : Ramathibodi Hospital
Strategic Timing of Antiretroviral Treatment
Bangkok : Chulalongkorn University Hospital
Strategic Timing of Antiretroviral Treatment
Bangkok noi : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Bangkok Noi : Siriraj Hospital
Strategic Timing of Antiretroviral Treatment
Chantaburi : Prapokklao Hospital CRS (8354)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chiang Mai : Chaing Mai University (20101)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chiang Mai : Sanpatong Hospital
Strategic Timing of Antiretroviral Treatment
Chiang Mai : Research Institute for Health Sciences (RIHES)
Strategic Timing of Antiretroviral Treatment
Chiang Rai : Chiang Rai Regional Hospital CRS (8352)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chiangmai : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Chiangrai : Chiangrai Prachanukroh Hospital
Strategic Timing of Antiretroviral Treatment
Chonburi : Chonburi Hosp. CRS (8356)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chonburi : Chonburi Regional Hospital
Strategic Timing of Antiretroviral Treatment
Khon Kaen :
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents
Khon Kaen : Khon Kaen University, Srinagarind Hospital
Strategic Timing of Antiretroviral Treatment
Nonthaburi : Bamrasnaradura Institute
Strategic Timing of Antiretroviral Treatment
Pathumwan : The Thai Red Cross AIDS Research Centre
Bone Health and Vitamin D Status
Phayao : Phayao Provincial Hospital CRS (8353)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Uganda
Entebbe : MRC UVRI Uganda Research Unit on AIDS
Strategic Timing of Antiretroviral Treatment
Kampala :
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents
Kampala : Makerere University - JHU Research Collaboration (30293)
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Kampala : Joint Clinical Research Center (JCRC)
Strategic Timing of Antiretroviral Treatment
Kampala : Makerere University- JHU Research Collaboration {MUJHU CARE LTD} CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
United Kingdom
Belfast : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Belfast : Belfast Health and Social Care Trust (RVH)
Strategic Timing of Antiretroviral Treatment
Birmingham :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Birmingham : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Birmingham : Queen Elizabeth Hospital Birmingham
Strategic Timing of Antiretroviral Treatment
View More »
Birmingham : Birmingham Heartlands Hospital
Strategic Timing of Antiretroviral Treatment
Birmingham : Heart of England NHS Foundation Trust
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
Bournemouth : Royal Bournemouth Hospital
Strategic Timing of Antiretroviral Treatment
Brighton : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Brighton : Brighton and Sussex University Hospitals NHS Trust
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Brighton : Brighton and Sussex University Hospitals NHS Trust
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Brighton : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Brighton : Brighton and Sussex University Hospitals NHS Trust
Strategic Timing of Antiretroviral Treatment
Cottingham : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Coventry : Coventry and Warwickshire NHS partnership Trust
Strategic Timing of Antiretroviral Treatment
Crumpsall, Manchester : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Edinburgh : Western General Hospital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Edinburgh : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Glasgow :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Gloucester : Gloucestershire Royal Hospital
Strategic Timing of Antiretroviral Treatment
Leicester : Leicester Royal Infirmary
Strategic Timing of Antiretroviral Treatment
Liverpool : Updated
Telaprevir Open-Label Study in Co-Infected Patients
London : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
London :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
London : St Mary's Hospital, London
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
London : St. George's Hospital, London
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
London : C&W Hospital, London
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
London : Homerton University Hospital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
London : Chelsea & Westminster Hospital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
London : South London Healthcare NHS Trust
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
London : St. Thomas' Hospital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
London : Royal Free Hampstead NHS Trust
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
London : Chelsea and Westminster
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
London : Collaborative HIV Paediatric Study
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
London : European Collaborative Study
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
London : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
London : Harrison Wing St Thomas' Hospital
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
London : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
London : Chelsea and Westminster Hospital
Strategic Timing of Antiretroviral Treatment
London : Guy's and St.Thomas' NHS Foundation Trust
Strategic Timing of Antiretroviral Treatment
London : University College London Medical School
Strategic Timing of Antiretroviral Treatment
London : Imperial College Healthcare NHS Trust
Strategic Timing of Antiretroviral Treatment
London : Royal Free London NHS Foundation Trust
Strategic Timing of Antiretroviral Treatment
London : St. George's Healthcare NHS Trust
Strategic Timing of Antiretroviral Treatment
London : Barts Health NHS Trust
Strategic Timing of Antiretroviral Treatment
London : South London Healthcare NHS Trust
Strategic Timing of Antiretroviral Treatment
London : Updated
Telaprevir Open-Label Study in Co-Infected Patients
London : St. Mary's Hospital
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
Manchester : Updated
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Manchester : North Manchester General Hospital
Strategic Timing of Antiretroviral Treatment
Middlesbrough : The James Cook University Hospital
Strategic Timing of Antiretroviral Treatment
Newcastle upon Tyne : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Plymouth : Updated
Telaprevir Open-Label Study in Co-Infected Patients
Reading : Royal Berkshire Hospital
Strategic Timing of Antiretroviral Treatment
Sally Oak : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Sheffield : Sheffield Teaching Hospital NHS Foundation Trust
Strategic Timing of Antiretroviral Treatment
Shoreham, West Sussex : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Stoke on Trent, Staffordshire : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Zimbabwe
Chitungwiza : St Mary's CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Chitungwiza : Seke North CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Harare : UZ-Parirenyatwa CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
